Lmcg Investments LLC Lowers Stake in Regeneron Pharmaceuticals, Inc. $REGN

Lmcg Investments LLC decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 38,979 shares of the biopharmaceutical company’s stock after selling 842 shares during the quarter. Regeneron Pharmaceuticals accounts for about 1.8% of Lmcg Investments LLC’s investment portfolio, making the stock its 10th largest position. Lmcg Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $30,117,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. WPG Advisers LLC raised its position in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares during the period. SHP Wealth Management bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $26,000. Titan Wealth CI Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $29,000. Board of the Pension Protection Fund bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth $31,000. Finally, Kemnay Advisory Services Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth $31,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 4.1%

Shares of Regeneron Pharmaceuticals stock opened at $676.23 on Wednesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $537.45 and a twelve month high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $648.64 and a 200-day moving average price of $724.11. The firm has a market cap of $71.49 billion, a price-to-earnings ratio of 16.48, a PEG ratio of 1.43 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same period in the prior year, the company earned $8.22 earnings per share. The firm’s revenue was up 19.0% on a year-over-year basis. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.46 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were issued a $0.94 dividend. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Benchmark upgraded Regeneron to buy from hold, signaling improved confidence in the stock’s outlook. Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Buy at Benchmark
• Positive Sentiment: Truist kept a buy rating and reiterated a new price target of $769, suggesting meaningful upside from current levels despite a slight target cut. Regeneron Pharmaceuticals had its price target lowered by Truist Financial Corporation
• Positive Sentiment: HSBC also maintained a buy rating after trimming its target to $880, reinforcing the view that analysts still see room for gains. Regeneron Pharmaceuticals had its price target lowered by HSBC Holdings plc
• Positive Sentiment: Zacks highlighted Regeneron as a strong value stock and noted its favorable earnings surprise history, which may be building investor confidence ahead of the next report. Here's Why Regeneron (REGN) is a Strong Value Stock
• Neutral Sentiment: Royal Bank of Canada lowered its target to $696 and kept a sector perform rating, which is a more cautious signal but still implies modest upside. Regeneron Pharmaceuticals had its price target lowered by Royal Bank Of Canada
• Neutral Sentiment: Jim Cramer’s comments that biotech could become “the hottest group in the market” added sector-wide optimism, but this was a broad industry call rather than Regeneron-specific news. Jim Cramer Calls Biotech “The Hottest Group in the Market”
• Negative Sentiment: Director Arthur F. Ryan sold 200 shares in a pre-arranged 10b5-1 transaction, which can sometimes weigh on sentiment even though the sale was relatively small. SEC filing for director sale
• Negative Sentiment: Cantor Fitzgerald and RBC both trimmed their price targets this week, suggesting analysts have slightly more tempered expectations for near-term upside. Regeneron price target changes

Analysts Set New Price Targets

REGN has been the subject of several recent research reports. Sanford C. Bernstein cut their price target on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a report on Wednesday, April 8th. HSBC decreased their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research note on Monday. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating for the company in a research note on Tuesday. Barclays cut their price objective on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Finally, Royal Bank Of Canada decreased their target price on shares of Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating on the stock in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $790.46.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.